INDOCOPharmaceuticals
Indoco Remedies Ltd — Cash Flow Statement
₹164.00
-6.69%
Indoco Remedies Ltd Cash Flow Statement (Annual)
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Net Long Term Debt Issuance | 159.08 Cr | 51.72 Cr | 54.38 Cr | -0.40 Cr | — |
| Long Term Debt Payments | -41.91 Cr | -51.28 Cr | -40.62 Cr | -97.90 Cr | — |
| Long Term Debt Issuance | 200.99 Cr | 103.00 Cr | 95.00 Cr | 97.50 Cr | — |
| Investing Cash Flow | -259.79 Cr | -301.70 Cr | -208.17 Cr | -121.41 Cr | — |
| Net Other Investing Changes | 4.50 Cr | -7.06 Cr | -0.11 Cr | 2.61 Cr | — |
| Interest Received Cfi | 11.59 Cr | 6.59 Cr | 0.46 Cr | 0.36 Cr | — |
| Dividends Received Cfi | 0.00 | 0.00 | 39000.00 | 29000.00 | — |
| Net Investment Purchase And Sale | 7.90 Cr | -6.24 Cr | -2.55 Cr | -15000.00 | — |
| Sale Of Investment | 7.90 Cr | 0.00 | — | — | — |
| Purchase Of Investment | 0.00 | -6.24 Cr | -2.55 Cr | -15000.00 | — |
| Net Business Purchase And Sale | 0.00 | -33.06 Cr | — | — | — |
| Purchase Of Business | 0.00 | -33.06 Cr | — | — | — |
| Net PPE Purchase And Sale | 3.55 Cr | 1.68 Cr | 1.16 Cr | 0.94 Cr | — |
| Sale Of PPE | 3.55 Cr | 1.68 Cr | 1.16 Cr | 0.94 Cr | — |
| Capital Expenditure Reported | -258.43 Cr | -179.03 Cr | -207.25 Cr | -125.32 Cr | — |
| Operating Cash Flow | 90.76 Cr | 176.79 Cr | 178.83 Cr | 173.83 Cr | — |
| Taxes Refund Paid | -16.60 Cr | -29.10 Cr | -61.65 Cr | -41.08 Cr | — |
| Change In Working Capital | -32.48 Cr | -77.42 Cr | -73.19 Cr | -108.79 Cr | — |
| Change In Other Current Liabilities | -0.33 Cr | 26.87 Cr | -8.75 Cr | 15.84 Cr | — |
| Change In Other Current Assets | -32.08 Cr | -45.88 Cr | 32.80 Cr | -10.93 Cr | — |
| Change In Payable | 29.18 Cr | -7.48 Cr | -8.65 Cr | 21.43 Cr | — |
| Change In Inventory | -52.45 Cr | 15.57 Cr | -15.47 Cr | -72.66 Cr | — |
| Change In Receivables | 30.99 Cr | -65.51 Cr | -78.78 Cr | -58.78 Cr | — |
| Other Non Cash Items | 44.28 Cr | 30.42 Cr | 25.47 Cr | 12.99 Cr | — |
| Stock Based Compensation | 1.87 Cr | 2.69 Cr | 0.66 Cr | 0.00 | — |
| Provisionand Write Offof Assets | 1.59 Cr | 8.04 Cr | 15.60 Cr | 15.14 Cr | — |
| Depreciation And Amortization | 98.25 Cr | 87.98 Cr | 70.61 Cr | 77.20 Cr | — |
| Free Cash Flow | -167.67 Cr | -2.24 Cr | -28.42 Cr | 48.50 Cr | — |
| Repayment Of Debt | -41.91 Cr | -51.28 Cr | -40.62 Cr | -97.90 Cr | — |
| Issuance Of Debt | 200.99 Cr | 103.00 Cr | 95.00 Cr | 97.50 Cr | — |
| Issuance Of Capital Stock | 1.59 Cr | 0.77 Cr | 0.00 | — | — |
| Capital Expenditure | -258.43 Cr | -179.03 Cr | -207.25 Cr | -125.32 Cr | — |
| End Cash Position | 7.06 Cr | 7.47 Cr | 10.92 Cr | 17.47 Cr | — |
| Beginning Cash Position | 7.47 Cr | 9.99 Cr | 17.47 Cr | 9.42 Cr | — |
| Changes In Cash | -0.41 Cr | -2.52 Cr | -6.54 Cr | 8.05 Cr | — |
| Financing Cash Flow | 168.62 Cr | 122.39 Cr | 22.80 Cr | -44.37 Cr | — |
| Interest Paid Cff | -54.98 Cr | -35.87 Cr | -27.20 Cr | -14.99 Cr | — |
| Cash Dividends Paid | -13.90 Cr | -20.71 Cr | -20.72 Cr | -13.79 Cr | — |
| Common Stock Dividend Paid | -13.90 Cr | -20.71 Cr | -20.72 Cr | -13.79 Cr | — |
| Net Common Stock Issuance | 1.59 Cr | 0.77 Cr | 0.00 | — | — |
| Common Stock Issuance | 1.59 Cr | 0.77 Cr | 0.00 | — | — |
| Net Issuance Payments Of Debt | 241.14 Cr | 182.03 Cr | 72.50 Cr | -14.31 Cr | — |
| Net Short Term Debt Issuance | 82.06 Cr | 130.31 Cr | 18.12 Cr | -13.90 Cr | — |
| Depreciation | 98.25 Cr | 87.98 Cr | 56.36 Cr | 50.76 Cr | — |
| Gain Loss On Investment Securities | -0.66 Cr | -40000.00 | -39000.00 | -29000.00 | — |
| Net Foreign Currency Exchange Gain Loss | 1.39 Cr | 0.57 Cr | 7.30 Cr | -20.46 Cr | — |
| Gain Loss On Sale Of PPE | 0.50 Cr | 0.38 Cr | 1.26 Cr | 0.51 Cr | — |
| Net Income From Continuing Operations | -8.37 Cr | 141.70 Cr | 192.79 Cr | 236.57 Cr | — |
| Other Cash Adjustment Outside Changein Cash | — | 0.62 Cr | 0.01 Cr | — | — |
| Amortization Cash Flow | — | 29.41 Cr | 14.24 Cr | 26.44 Cr | 23.38 Cr |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on Indoco Remedies Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.